{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:29:04Z","timestamp":1790710144976,"version":"4.1.0"},"reference-count":139,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T00:00:00Z","timestamp":1692316800000},"content-version":"vor","delay-in-days":504,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["RF-2016-02364384"],"award-info":[{"award-number":["RF-2016-02364384"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s13311-022-01181-3","type":"journal-article","created":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T15:23:22Z","timestamp":1644852202000},"page":"897-910","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Antibody Therapies in Autoimmune Neuromuscular Junction Disorders: Approach to Myasthenic Crisis and Chronic Management"],"prefix":"10.1016","volume":"19","author":[{"given":"Fiammetta","family":"Vanoli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9810-5737","authenticated-orcid":false,"given":"Renato","family":"Mantegazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1007\/s13311-022-01181-3_bib1","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/nyas.13592","article-title":"Serological and experimental studies in different forms of myasthenia gravis","volume":"1413","author":"Vincent","year":"2018","journal-title":"Ann N Y Acad Sci"},{"key":"10.1007\/s13311-022-01181-3_bib2","doi-asserted-by":"crossref","DOI":"10.1177\/1756286419832242","article-title":"Understanding the burden of refractory myasthenia gravis","volume":"12","author":"Schneider-Gold","year":"2019","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1007\/s13311-022-01181-3_bib3","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2147\/IJGM.S88552","article-title":"Animal models of myasthenia gravis: utility and limitations","volume":"9","author":"Mantegazza","year":"2016","journal-title":"International journal of general medicine"},{"issue":"10","key":"10.1007\/s13311-022-01181-3_bib4","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"The Lancet Neurology"},{"issue":"4","key":"10.1007\/s13311-022-01181-3_bib5","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1001\/jamaneurol.2014.4103","article-title":"A genome-wide association study of myasthenia gravis","volume":"72","author":"Renton","year":"2015","journal-title":"JAMA Neurol"},{"issue":"6","key":"10.1007\/s13311-022-01181-3_bib6","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1002\/ana.23691","article-title":"Risk for myasthenia gravis maps to a 151Pro\u2192 Ala change in TNIP1 and to human leukocyte antigen-B* 08","volume":"72","author":"Gregersen","year":"2012","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1007\/s13311-022-01181-3_bib7","doi-asserted-by":"crossref","first-page":"769","DOI":"10.2119\/molmed.2015.00232","article-title":"Genome-wide association study of late-onset myasthenia gravis: confirmation of TNFRSF11A and identification of ZBTB10 and three distinct HLA associations","volume":"21","author":"Seldin","year":"2015","journal-title":"Mol Med"},{"issue":"3","key":"10.1007\/s13311-022-01181-3_bib8","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/ana.26169","article-title":"Genomic insights into myasthenia gravis identify distinct immunological mechanisms in early and late onset disease","volume":"90","author":"Handunnetthi","year":"2021","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1007\/s13311-022-01181-3_bib9","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/joa.12034","article-title":"The role of muscle-specific tyrosine kinase (MuSK) and mystery of MuSK myasthenia gravis","volume":"224","author":"Koneczny","year":"2014","journal-title":"J Anat"},{"key":"10.1007\/s13311-022-01181-3_bib10","doi-asserted-by":"crossref","unstructured":"Haddad G, Lorenzen JM, Ma H, de Haan N, Seeger H, Zaghrini C, Brandt S, K\u00f6lling M, Wegmann U, Kiss B, P\u00e1l G. Altered glycosylation of IgG4 promotes lectin complement pathway activation in anti-PLA2R1\u2013associated membranous nephropathy. J Clin Invest. 2021;131(5).","DOI":"10.1172\/JCI140453"},{"issue":"4","key":"10.1007\/s13311-022-01181-3_bib11","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/ana.20061","article-title":"Detection and characterization of MuSK antibodies in seronegative myasthenia gravis","volume":"55","author":"McConville","year":"2004","journal-title":"Ann Neurol"},{"issue":"52","key":"10.1007\/s13311-022-01181-3_bib12","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jaut.2013.12.004","article-title":"A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis","volume":"1","author":"Zisimopoulou","year":"2014","journal-title":"J Autoimmun"},{"issue":"2","key":"10.1007\/s13311-022-01181-3_bib13","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/ana.22312","article-title":"Autoantibodies to low-density lipoprotein receptor\u2013related protein 4 in myasthenia gravis","volume":"69","author":"Higuchi","year":"2011","journal-title":"Ann Neurol"},{"issue":"297","key":"10.1007\/s13311-022-01181-3_bib14","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.expneurol.2017.08.006","article-title":"Immunization of mice with LRP4 induces myasthenia similar to MuSK-associated myasthenia gravis","volume":"1","author":"Mori","year":"2017","journal-title":"Exp Neurol"},{"issue":"373","key":"10.1007\/s13311-022-01181-3_bib15","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.neuroscience.2018.01.015","article-title":"Induction of anti-agrin antibodies causes myasthenia gravis in mice","volume":"1","author":"Yan","year":"2018","journal-title":"Neuroscience"},{"issue":"12","key":"10.1007\/s13311-022-01181-3_bib16","doi-asserted-by":"crossref","first-page":"5190","DOI":"10.1172\/JCI66039","article-title":"Antibodies against low-density lipoprotein receptor\u2013related protein 4 induce myasthenia gravis","volume":"123","author":"Shen","year":"2013","journal-title":"J Clin Investig"},{"issue":"1\u20132","key":"10.1007\/s13311-022-01181-3_bib17","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jns.2014.12.015","article-title":"Collagen Q\u2013a potential target for autoantibodies in myasthenia gravis","volume":"348","author":"Katarzyna","year":"2015","journal-title":"J Neurol Sci"},{"key":"10.1007\/s13311-022-01181-3_bib18","doi-asserted-by":"crossref","unstructured":"Agius MA, Zhu S, Kirvan CA, Schafer AL, Lin MY, Fairclough RH, OGER JJ, Aziz T, Aarli JA. Rapsyn antibodies in myasthenia gravis a. Annals of the New York Academy of Sciences. 1998 May;841(1):516\u201321.","DOI":"10.1111\/j.1749-6632.1998.tb10972.x"},{"issue":"3","key":"10.1007\/s13311-022-01181-3_bib19","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1001\/archneur.62.3.442","article-title":"Striational antibodies in myasthenia gravis: reactivity and possible clinical significance","volume":"62","author":"Romi","year":"2005","journal-title":"Arch Neurol"},{"issue":"10","key":"10.1007\/s13311-022-01181-3_bib20","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.autrev.2014.08.039","article-title":"Cortactin autoantibodies in myasthenia gravis","volume":"13","author":"Gallardo","year":"2014","journal-title":"Autoimmun Rev"},{"issue":"6","key":"10.1007\/s13311-022-01181-3_bib21","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1001\/archneur.58.6.885","article-title":"Anti-titin antibodies in myasthenia gravis: tight association with thymoma and heterogeneity of nonthymoma patients","volume":"58","author":"Yamamoto","year":"2001","journal-title":"Arch Neurol"},{"key":"10.1007\/s13311-022-01181-3_bib22","doi-asserted-by":"crossref","unstructured":"Romi F, Suzuki S, Suzuki N, Petzold A, Plant GT, Gilhus NE. Anti-voltage-gated potassium channel Kv1. 4 antibodies in myasthenia gravis. J Neurol. 2012;259(7):1312\u20136.","DOI":"10.1007\/s00415-011-6344-y"},{"issue":"6","key":"10.1007\/s13311-022-01181-3_bib23","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1084\/jem.20011626","article-title":"Short-lived and long-lived bone marrow plasma cells are derived from a novel precursor population","volume":"195","author":"O'Connor","year":"2002","journal-title":"J Exp Med"},{"issue":"16","key":"10.1007\/s13311-022-01181-3_bib24","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/0161-5890(95)00101-8","article-title":"Evidence for an antigen-driven selection process in human autoantibodies against acetylcholine receptor","volume":"32","author":"Cardona","year":"1995","journal-title":"Mol Immunol"},{"issue":"5","key":"10.1007\/s13311-022-01181-3_bib25","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.4049\/jimmunol.1501339","article-title":"Autoreactive T cells from patients with myasthenia gravis are characterized by elevated IL-17, IFN-\u03b3, and GM-CSF and diminished IL-10 production","volume":"196","author":"Cao","year":"2016","journal-title":"J Immunol"},{"issue":"1\u20132","key":"10.1007\/s13311-022-01181-3_bib26","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0165-5728(00)00250-2","article-title":"T cell recognition of muscle acetylcholine receptor in ocular myasthenia gravis","volume":"108","author":"Wang","year":"2000","journal-title":"J Neuroimmunol"},{"issue":"52","key":"10.1007\/s13311-022-01181-3_bib27","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jaut.2013.12.005","article-title":"Characterization of CD4 and CD8 T cell responses in MuSK myasthenia gravis","volume":"1","author":"Yi","year":"2014","journal-title":"J Autoimmun"},{"key":"10.1007\/s13311-022-01181-3_bib28","doi-asserted-by":"crossref","unstructured":"Yilmaz V, Oflazer P, Aysal F, Durmus H, Poulas K, Yentur SP, Gulsen-Parman Y, Tzartos S, Marx A, Tuzun E, Deymeer F. Differential cytokine changes in patients with myasthenia gravis with antibodies against AChR and MuSK. PloS One. 2015;10(4):e0123546.","DOI":"10.1371\/journal.pone.0123546"},{"issue":"2","key":"10.1007\/s13311-022-01181-3_bib29","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1182\/blood-2003-11-3900","article-title":"Functional defect of regulatory CD4+ CD25+ T cells in the thymus of patients with autoimmune myasthenia gravis","volume":"105","author":"Balandina","year":"2005","journal-title":"Blood"},{"issue":"3","key":"10.1007\/s13311-022-01181-3_bib30","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.clim.2012.09.012","article-title":"Impaired regulatory function in circulating CD4+ CD25highCD127low\/\u2212 T cells in patients with myasthenia gravis","volume":"145","author":"Thiruppathi","year":"2012","journal-title":"Clin Immunol"},{"issue":"52","key":"10.1007\/s13311-022-01181-3_bib31","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jaut.2013.12.015","article-title":"Both Treg cells and Tconv cells are defective in the myasthenia gravis thymus: roles of IL-17 and TNF-\u03b1","volume":"1","author":"Gradolatto","year":"2014","journal-title":"J Autoimmun"},{"key":"10.1007\/s13311-022-01181-3_bib32","doi-asserted-by":"crossref","unstructured":"Zhu Y, Zou L, Liu YC. T follicular helper cells, T follicular regulatory cells and autoimmunity. International immunology. 2016 Apr 1;28(4):173-9","DOI":"10.1093\/intimm\/dxv079"},{"issue":"1","key":"10.1007\/s13311-022-01181-3_bib33","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/icb.2013.55","article-title":"Human T follicular helper (Tfh) cells and disease","volume":"92","author":"Ma","year":"2014","journal-title":"Immunol Cell Biol"},{"issue":"7","key":"10.1007\/s13311-022-01181-3_bib34","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.4049\/jimmunol.1500725","article-title":"Augmentation of circulating follicular helper T cells and their impact on autoreactive B cells in myasthenia gravis","volume":"197","author":"Zhang","year":"2016","journal-title":"J Immunol"},{"issue":"1","key":"10.1007\/s13311-022-01181-3_bib35","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/icb.2013.68","article-title":"Follicular helper T-cell memory: establishing new frontiers during antibody response","volume":"92","author":"Tsai","year":"2014","journal-title":"Immunol Cell Biol"},{"issue":"1","key":"10.1007\/s13311-022-01181-3_bib36","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.immuni.2010.12.012","article-title":"Human blood CXCR5+ CD4+ T cells are counterparts of T follicular cells and contain specific subsets that differentially support antibody secretion","volume":"34","author":"Morita","year":"2011","journal-title":"Immunity"},{"issue":"9","key":"10.1007\/s13311-022-01181-3_bib37","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.it.2014.06.002","article-title":"Phenotype and functions of memory Tfh cells in human blood","volume":"35","author":"Schmitt","year":"2014","journal-title":"Trends Immunol"},{"key":"10.1007\/s13311-022-01181-3_bib38","doi-asserted-by":"crossref","unstructured":"Li Y, Guptill JT, Russo MA, Howard Jr JF, Massey JM, Juel VC, Hobson-Webb LD, Emmett D, Chopra M, Raja S, Liu W. Imbalance in T follicular helper cells producing IL-17 promotes pro-inflammatory responses in MuSK antibody positive myasthenia gravis. J Neuroimmunol. 2020;345:577279.","DOI":"10.1016\/j.jneuroim.2020.577279"},{"issue":"1","key":"10.1007\/s13311-022-01181-3_bib39","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/imr.12411","article-title":"T follicular regulatory cells","volume":"271","author":"Sage","year":"2016","journal-title":"Immunol Rev"},{"key":"10.1007\/s13311-022-01181-3_bib40","doi-asserted-by":"crossref","unstructured":"Ashida S, Ochi H, Hamatani M, Fujii C, Kimura K, Okada Y, Hashi Y, Kawamura K, Ueno H, Takahashi R, Mizuno T. Immune skew of circulating follicular helper T cells associates with myasthenia gravis severity. Neurology-Neuroimmunology Neuroinflammation. 2021;8(2).","DOI":"10.1212\/NXI.0000000000000945"},{"issue":"630","key":"10.1007\/s13311-022-01181-3_bib41","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.neulet.2016.07.049","article-title":"Imbalance of circulating CD4+ CXCR5+ FOXP3+ Tfr-like cells and CD4+ CXCR5+ FOXP3\u2212 Tfh-like cells in myasthenia gravis","volume":"6","author":"Wen","year":"2016","journal-title":"Neurosci Lett"},{"issue":"1\u20132","key":"10.1007\/s13311-022-01181-3_bib42","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.imlet.2013.07.005","article-title":"The CD40\/CD40L system: a new therapeutic target for disease","volume":"153","author":"Zhang","year":"2013","journal-title":"Immunol Lett"},{"issue":"13","key":"10.1007\/s13311-022-01181-3_bib43","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1056\/NEJM197603252941303","article-title":"Detection of anti-acetylcholine receptor factors in serum and thymus from patients with myasthenia gravis","volume":"294","author":"Mittag","year":"1976","journal-title":"N Engl J Med"},{"issue":"8059","key":"10.1007\/s13311-022-01181-3_bib44","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0140-6736(78)90073-9","article-title":"In-vitro synthesis of anti-acetylcholine-receptor antibody by thymic lymphocytes in myasthenia gravis","volume":"311","author":"Vincent","year":"1978","journal-title":"The Lancet"},{"issue":"1\u20132","key":"10.1007\/s13311-022-01181-3_bib45","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jneuroim.2006.05.023","article-title":"The thymus is a source of B cell-survival factors\u2013APRIL and BAFF\u2013in myasthenia gravis","volume":"178","author":"Thangarajh","year":"2006","journal-title":"J Neuroimmunol"},{"issue":"9","key":"10.1007\/s13311-022-01181-3_bib46","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.autrev.2013.03.007","article-title":"The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes","volume":"12","author":"Marx","year":"2013","journal-title":"Autoimmun Rev"},{"issue":"4","key":"10.1007\/s13311-022-01181-3_bib47","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/mus.22103","article-title":"The thymus in myasthenia gravis: site of \u201cinnate autoimmunity\u201d?","volume":"44","author":"Cavalcante","year":"2011","journal-title":"Muscle Nerve"},{"key":"10.1007\/s13311-022-01181-3_bib48","doi-asserted-by":"crossref","unstructured":"Cron M, Maillard S, Villegas J, Truffault F, Sudres M, Dragin N, Berrih-Aknin S, Le Panse R. Thymus involvement in early-onset myasthenia gravis. In 13th International Conference on Myasthenia Gravis and Related Disorders 2017;1412(1):137\u2013145.","DOI":"10.1111\/nyas.13519"},{"issue":"10","key":"10.1007\/s13311-022-01181-3_bib49","doi-asserted-by":"crossref","first-page":"5941","DOI":"10.4049\/jimmunol.174.10.5941","article-title":"Effects of cytokines on acetylcholine receptor expression: implications for myasthenia gravis","volume":"174","author":"Po\u00eba-Guyon","year":"2005","journal-title":"J Immunol"},{"issue":"7156","key":"10.1007\/s13311-022-01181-3_bib50","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/nature06066","article-title":"An IRF8-binding promoter variant and AIRE control CHRNA1 promiscuous expression in thymus","volume":"448","author":"Giraud","year":"2007","journal-title":"Nature"},{"issue":"49","key":"10.1007\/s13311-022-01181-3_bib51","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.coi.2017.07.006","article-title":"Pathophysiology and immunological profile of myasthenia gravis and its subgroups","volume":"1","author":"Romi","year":"2017","journal-title":"Curr Opin Immunol"},{"issue":"52","key":"10.1007\/s13311-022-01181-3_bib52","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jaut.2013.12.011","article-title":"Myasthenia gravis: a comprehensive review of immune dysregulation and etiological mechanisms","volume":"1","author":"Berrih-Aknin","year":"2014","journal-title":"J Autoimmun"},{"issue":"5\u20136","key":"10.1007\/s13311-022-01181-3_bib53","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3109\/08916930903555935","article-title":"Thymoma and paraneoplastic myasthenia gravis","volume":"43","author":"Marx","year":"2010","journal-title":"Autoimmunity"},{"issue":"9","key":"10.1007\/s13311-022-01181-3_bib54","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.autrev.2013.03.010","article-title":"Etiology of myasthenia gravis: innate immunity signature in pathological thymus","volume":"12","author":"Cavalcante","year":"2013","journal-title":"Autoimmun Rev"},{"issue":"5","key":"10.1007\/s13311-022-01181-3_bib55","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1212\/WNL.48.5.1253","article-title":"Myasthenic crisis: clinical features, mortality, complications, and risk factors for prolonged intubation","volume":"48","author":"Thomas","year":"1997","journal-title":"Neurology"},{"issue":"10","key":"10.1007\/s13311-022-01181-3_bib56","doi-asserted-by":"crossref","first-page":"839","DOI":"10.2165\/11593110-000000000-00000","article-title":"Fluoroquinolone-associated myasthenia gravis exacerbation","volume":"34","author":"Jones","year":"2011","journal-title":"Drug Saf"},{"issue":"17","key":"10.1007\/s13311-022-01181-3_bib57","first-page":"1283","article-title":"Fluoroquinolone associated myasthenia gravis exacerbation: clinical analysis of 9 cases","volume":"93","author":"Wang","year":"2013","journal-title":"Zhonghua Yi Xue Za Zhi"},{"issue":"6","key":"10.1007\/s13311-022-01181-3_bib58","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1002\/mus.26689","article-title":"Factors associated with acute exacerbations of myasthenia gravis","volume":"60","author":"Gummi","year":"2019","journal-title":"Muscle Nerve"},{"issue":"6","key":"10.1007\/s13311-022-01181-3_bib59","doi-asserted-by":"crossref","first-page":"834","DOI":"10.7326\/0003-4819-83-6-834","article-title":"\u03b2-blockers and myasthenia gravis","volume":"83","author":"Herishanu","year":"1975","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1007\/s13311-022-01181-3_bib60","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/0002-9394(87)90366-7","article-title":"Timolol-associated myasthenia gravis","volume":"98","author":"Coppeto","year":"1984","journal-title":"Am J Ophthalmol"},{"key":"10.1007\/s13311-022-01181-3_bib61","doi-asserted-by":"crossref","unstructured":"Safa H, Johnson DH, Trinh VA, Rodgers TE, Lin H, Suarez-Almazor ME, Fa'ak F, Saberian C, Yee C, Davies MA, Tummala S. Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature. J Immunother Cancer. 2019;7(1):1\u20131.","DOI":"10.1186\/s40425-019-0774-y"},{"issue":"8","key":"10.1007\/s13311-022-01181-3_bib62","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1210\/jc.2018-00359","article-title":"Alemtuzumab-induced thyroid dysfunction exhibits distinctive clinical and immunological features","volume":"103","author":"Pariani","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"10.1007\/s13311-022-01181-3_bib63","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1177\/1352458519851219","article-title":"Emerging safety issues in alemtuzumab-treated MS patients","volume":"25","author":"Killestein","year":"2019","journal-title":"Mult Scler J"},{"issue":"13","key":"10.1007\/s13311-022-01181-3_bib64","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1212\/WNL.0000000000006251","article-title":"Myasthenia gravis following alemtuzumab therapy for multiple sclerosis","volume":"91","author":"Midaglia","year":"2018","journal-title":"Neurology"},{"key":"10.1007\/s13311-022-01181-3_bib65","doi-asserted-by":"crossref","unstructured":"Gajdos P, Chevret S, Toyka KV. Intravenous immunoglobulin for myasthenia gravis. Cochrane Database of Systematic Reviews. 2008(1).","DOI":"10.1002\/14651858.CD002277.pub3"},{"key":"10.1007\/s13311-022-01181-3_bib66","doi-asserted-by":"crossref","unstructured":"Gajdos P, Chevret S, Clair B, Tranchant C, Chastang C, Myasthenia Gravis Clinical Study Group. Clinical trial of plasma exchange and high\u2010dose intravenous immunoglobulin in myasthenia gravis. Ann Neurol. 1997;41(6):789\u201396.","DOI":"10.1002\/ana.410410615"},{"issue":"23","key":"10.1007\/s13311-022-01181-3_bib67","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1212\/WNL.0b013e31821e5505","article-title":"Comparison of IVIg and PLEX in patients with myasthenia gravis","volume":"76","author":"Barth","year":"2011","journal-title":"Neurology"},{"issue":"11","key":"10.1007\/s13311-022-01181-3_bib68","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1212\/01.wnl.0000256698.69121.45","article-title":"IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial","volume":"68","author":"Zinman","year":"2007","journal-title":"Neurology"},{"key":"10.1007\/s13311-022-01181-3_bib69","doi-asserted-by":"crossref","unstructured":"Gajdos P, Tranchant C, Clair B, Bolgert F, Eymard B, Stojkovic T, Attarian S, Chevret S, Myasthenia gravis clinical study group. Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin: a randomized double-blind clinical trial. Arch Neurol. 2005;62(11):1689\u201393.","DOI":"10.1001\/archneur.62.11.1689"},{"key":"10.1007\/s13311-022-01181-3_bib70","unstructured":"Schuchardt V. Intravenous Immunoglobulin G (IVIG) for myasthenia gravis-short and long-term effects in comparison to other immune therapies. Kiehl MG, Nass WP, Volk HD. 2002:96\u2013103."},{"issue":"10","key":"10.1007\/s13311-022-01181-3_bib71","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.3389\/fimmu.2019.03052","article-title":"Antagonism of the neonatal Fc receptor as an emerging treatment for myasthenia gravis","volume":"10","author":"Gable","year":"2020","journal-title":"Front Immunol"},{"issue":"2","key":"10.1007\/s13311-022-01181-3_bib72","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/BF00315690","article-title":"A short plasma exchange protocol is effective in severe myasthenia gravis","volume":"238","author":"Antozzi","year":"1991","journal-title":"J Neurol"},{"issue":"4","key":"10.1007\/s13311-022-01181-3_bib73","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"issue":"10","key":"10.1007\/s13311-022-01181-3_bib74","doi-asserted-by":"crossref","first-page":"691","DOI":"10.2165\/11593300-000000000-00000","article-title":"Treatment of myasthenia gravis","volume":"31","author":"Maggi","year":"2011","journal-title":"Clin Drug Investig"},{"key":"10.1007\/s13311-022-01181-3_bib75","doi-asserted-by":"crossref","unstructured":"Mehndiratta MM, Pandey S, Kuntzer T. Acetylcholinesterase inhibitor treatment for myasthenia gravis. Cochrane Database of Systematic Reviews. 2014(10).","DOI":"10.1002\/14651858.CD006986.pub3"},{"key":"10.1007\/s13311-022-01181-3_bib76","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2147\/NDT.S8915","article-title":"Current and emerging therapies for the treatment of myasthenia gravis","volume":"7","author":"Mantegazza","year":"2011","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"3","key":"10.1007\/s13311-022-01181-3_bib77","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/cei.12217","article-title":"Myasthenia gravis: an update for the clinician","volume":"175","author":"Sieb","year":"2014","journal-title":"Clin Exp Immunol"},{"issue":"369","key":"10.1007\/s13311-022-01181-3_bib78","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.jns.2016.08.057","article-title":"Maintenance immunosuppression in myasthenia gravis","volume":"15","author":"Gotterer","year":"2016","journal-title":"J Neurol Sci"},{"key":"10.1007\/s13311-022-01181-3_bib79","doi-asserted-by":"crossref","unstructured":"Gilhus NE, Socrates T, Amelia E, Jacqueline P, Burns TM. Myasthenia gravis (Primer). Nature Reviews: Disease Primers. 2019;5(1).","DOI":"10.1038\/s41572-019-0079-y"},{"issue":"1","key":"10.1007\/s13311-022-01181-3_bib80","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1468-1331.2006.01538.x","article-title":"Myasthenia gravis in pregnancy and birth: identifying risk factors, optimising care","volume":"14","author":"Hoff","year":"2007","journal-title":"Eur J Neurol"},{"issue":"5","key":"10.1007\/s13311-022-01181-3_bib81","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1136\/jnnp-2013-305572","article-title":"Myasthenia in pregnancy: best practice guidelines from a UK multispecialty working group","volume":"85","author":"Norwood","year":"2014","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-022-01181-3_bib82","doi-asserted-by":"crossref","unstructured":"Goldstein LH, Dolinsky G, Greenberg R, Schaefer C, Cohen\u2010Kerem R, Diav\u2010Citrin O, Malm H, Reuvers\u2010Lodewijks ME, Rost van Tonningen\u2010van Driel MM, Arnon J, Ornoy A. Pregnancy outcome of women exposed to azathioprine during pregnancy. Birth Defects Res A Clin Mol Teratol. 2007;79(10):696\u2013701.","DOI":"10.1002\/bdra.20399"},{"issue":"2","key":"10.1007\/s13311-022-01181-3_bib83","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ejogrb.2005.01.002","article-title":"Myasthenia gravis: management issues during pregnancy","volume":"121","author":"Ferrero","year":"2005","journal-title":"European Journal of Obstetrics & Gynecology and Reproductive Biology"},{"issue":"5","key":"10.1007\/s13311-022-01181-3_bib84","first-page":"1499","article-title":"Pregnancy outcomes after maternal exposure to rituximab","volume":"117","author":"Chakravarty","year":"2011","journal-title":"Blood, The Journal of the American Society of Hematology"},{"key":"10.1007\/s13311-022-01181-3_bib85","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2147\/TCRM.S14015","article-title":"Current and emerging treatments for the management of myasthenia gravis","volume":"7","author":"Sathasivam","year":"2011","journal-title":"Ther Clin Risk Manag"},{"issue":"5","key":"10.1007\/s13311-022-01181-3_bib86","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/mus.21640","article-title":"Mycophenolate mofetil in AChR-antibody-positive myasthenia gravis: outcomes in 102 patients","volume":"41","author":"Hehir","year":"2010","journal-title":"Muscle & Nerve: Official Journal of the American Association of Electrodiagnostic Medicine"},{"issue":"2","key":"10.1007\/s13311-022-01181-3_bib87","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1177\/1756285615571873","article-title":"The emerging role of tacrolimus in myasthenia gravis","volume":"8","author":"Cruz","year":"2015","journal-title":"Ther Adv Neurol Disord"},{"issue":"3","key":"10.1007\/s13311-022-01181-3_bib88","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","article-title":"International consensus guidance for management of myasthenia gravis: 2020 update","volume":"96","author":"Narayanaswami","year":"2021","journal-title":"Neurology"},{"issue":"6","key":"10.1007\/s13311-022-01181-3_bib89","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1016\/S0022-5223(03)00938-3","article-title":"The immunologic role of thymectomy in the treatment of myasthenia gravis: implication of thymus-associated B-lymphocyte subset in reduction of the anti-acetylcholine receptor antibody titer","volume":"126","author":"Okumura","year":"2003","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"6","key":"10.1007\/s13311-022-01181-3_bib90","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1602489","article-title":"Randomized trial of thymectomy in myasthenia gravis","volume":"375","author":"Wolfe","year":"2016","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1007\/s13311-022-01181-3_bib91","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S1474-4422(18)30392-2","article-title":"Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial","volume":"18","author":"Wolfe","year":"2019","journal-title":"The Lancet Neurology"},{"issue":"1","key":"10.1007\/s13311-022-01181-3_bib92","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/nrd984","article-title":"Therapeutic antibodies for human diseases at the dawn of the twenty-first century","volume":"2","author":"Brekke","year":"2003","journal-title":"Nat Rev Drug Discovery"},{"key":"10.1007\/s13311-022-01181-3_bib93","doi-asserted-by":"crossref","first-page":"965","DOI":"10.2147\/TCRM.S204909","article-title":"The importance of early identification of infusion-related reactions to monoclonal antibodies","volume":"15","author":"C\u00e1ceres","year":"2019","journal-title":"Ther Clin Risk Manag"},{"issue":"3","key":"10.1007\/s13311-022-01181-3_bib94","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.21873\/anticanres.14062","article-title":"Systematic review on infusion reactions to and infusion rate of monoclonal antibodies used in cancer treatment","volume":"40","author":"Rombouts","year":"2020","journal-title":"Anticancer Res"},{"issue":"1","key":"10.1007\/s13311-022-01181-3_bib95","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1188\/07.CJON.S1.37-42","article-title":"Cytokine-release syndrome: overview and nursing implications","volume":"11","author":"Breslin","year":"2007","journal-title":"Clin J Oncol Nurs"},{"issue":"11","key":"10.1007\/s13311-022-01181-3_bib96","doi-asserted-by":"crossref","first-page":"240","DOI":"10.3389\/fimmu.2020.00240","article-title":"New approaches to targeting B cells for myasthenia gravis therapy","volume":"21","author":"Huda","year":"2020","journal-title":"Front Immunol"},{"key":"10.1007\/s13311-022-01181-3_bib97","doi-asserted-by":"crossref","unstructured":"Derer S, Kellner C, Berger S, Valerius T, Peipp M. Fc engineering: design, expression, and functional characterization of antibody variants with improved effector function. InAntibody Engineering 2012 (pp. 519\u2013536). Humana Press, Totowa, NJ.","DOI":"10.1007\/978-1-61779-974-7_30"},{"issue":"2","key":"10.1007\/s13311-022-01181-3_bib98","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1001\/archneur.62.2.258","article-title":"Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis","volume":"62","author":"Monson","year":"2005","journal-title":"Arch Neurol"},{"issue":"1","key":"10.1007\/s13311-022-01181-3_bib99","first-page":"1","article-title":"B-cell subpopulations in humans and their differential susceptibility to depletion with anti-CD20 monoclonal antibodies","volume":"15","author":"Leandro","year":"2013","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"10.1007\/s13311-022-01181-3_bib100","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1212\/WNL.0b013e3182407982","article-title":"Long-lasting treatment effect of rituximab in MuSK myasthenia","volume":"78","author":"D\u00edaz-Manera","year":"2012","journal-title":"Neurology"},{"issue":"5","key":"10.1007\/s13311-022-01181-3_bib101","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1177\/1756285611411503","article-title":"Response of patients with refractory myasthenia gravis to rituximab: a retrospective study","volume":"4","author":"Nowak","year":"2011","journal-title":"Ther Adv Neurol Disord"},{"issue":"2","key":"10.1007\/s13311-022-01181-3_bib102","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/mus.25597","article-title":"Rituximab treatment of myasthenia gravis: a systematic review","volume":"56","author":"Tandan","year":"2017","journal-title":"Muscle Nerve"},{"key":"10.1007\/s13311-022-01181-3_bib103","first-page":"e2182","article-title":"B cell targeted treatment in myasthenia gravis (BeatMG): a phase 2 trial of rituximab in myasthenia gravis","volume":"90","author":"Nowak","year":"2018","journal-title":"Neurology"},{"issue":"10","key":"10.1007\/s13311-022-01181-3_bib104","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1212\/WNL.0000000000004341","article-title":"Rituximab as treatment for anti-MuSK myasthenia gravis: multicenter blinded prospective review","volume":"89","author":"Hehir","year":"2017","journal-title":"Neurology"},{"issue":"11","key":"10.1007\/s13311-022-01181-3_bib105","doi-asserted-by":"crossref","first-page":"613","DOI":"10.3389\/fimmu.2020.00613","article-title":"long-lasting rituximab-induced reduction of specific\u2014but not total\u2014IgG4 in MuSK-positive myasthenia gravis","volume":"5","author":"Marino","year":"2020","journal-title":"Front Immunol"},{"key":"10.1007\/s13311-022-01181-3_bib106","doi-asserted-by":"crossref","unstructured":"Stathopoulos P, Kumar A, Nowak RJ, O'Connor KC. Autoantibody-producing plasmablasts after B cell depletion identified in muscle-specific kinase myasthenia gravis. JCI insight. 2017;2(17).","DOI":"10.1172\/jci.insight.94263"},{"key":"10.1007\/s13311-022-01181-3_bib107","doi-asserted-by":"crossref","unstructured":"Sharp MK. Ocrelizumab in primary progressive and relapsing multiple sclerosis. N England J Med. 2017;376(17):1692-.","DOI":"10.1056\/NEJMc1702076"},{"issue":"7","key":"10.1007\/s13311-022-01181-3_bib108","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1212\/WNL.0000000000000125","article-title":"Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: a phase 2 study","volume":"82","author":"Sorensen","year":"2014","journal-title":"Neurology"},{"issue":"3","key":"10.1007\/s13311-022-01181-3_bib109","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3233\/JND-170211","article-title":"Obinutuzumab plus chlorambucil in a patient with severe myasthenia gravis and chronic lymphocytic leukemia","volume":"4","author":"Russell","year":"2017","journal-title":"Journal of neuromuscular diseases"},{"issue":"2","key":"10.1007\/s13311-022-01181-3_bib110","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1177\/1352458517740641","article-title":"Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study","volume":"25","author":"Agius","year":"2019","journal-title":"Mult Scler J"},{"issue":"3","key":"10.1007\/s13311-022-01181-3_bib111","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1152\/physrev.00035.2007","article-title":"Evolution and function of the ADP ribosyl cyclase\/CD38 gene family in physiology and pathology","volume":"88","author":"Malavasi","year":"2008","journal-title":"Physiol Rev"},{"issue":"7","key":"10.1007\/s13311-022-01181-3_bib112","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1111\/bcp.14241","article-title":"Safety, tolerability, pharmacokinetics and pharmacodynamics of the anti-CD38 cytolytic antibody TAK-079 in healthy subjects","volume":"86","author":"Fedyk","year":"2020","journal-title":"Br J Clin Pharmacol"},{"issue":"16","key":"10.1007\/s13311-022-01181-3_bib113","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1056\/NEJMct1207259","article-title":"Belimumab for systemic lupus erythematosus","volume":"368","author":"Hahn","year":"2013","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1007\/s13311-022-01181-3_bib114","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s40265-018-0872-z","article-title":"Belimumab: a review in systemic lupus erythematosus","volume":"78","author":"Blair","year":"2018","journal-title":"Drugs"},{"issue":"1","key":"10.1007\/s13311-022-01181-3_bib115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12881-019-0906-8","article-title":"Associations of BAFF rs2893321 polymorphisms with myasthenia gravis susceptibility","volume":"20","author":"Deng","year":"2019","journal-title":"BMC Med Genet"},{"key":"10.1007\/s13311-022-01181-3_bib116","doi-asserted-by":"crossref","unstructured":"Hewett K, Sanders DB, Grove RA, Broderick CL, Rudo TJ, Bassiri A, Zvartau-Hind M, Bril V, BEL115123 Study Group. Randomized study of adjunctive belimumab in participants with generalized myasthenia gravis. Neurology. 2018;90(16):e1425\u201334.","DOI":"10.1212\/WNL.0000000000005323"},{"issue":"11","key":"10.1007\/s13311-022-01181-3_bib117","doi-asserted-by":"crossref","first-page":"6893","DOI":"10.4049\/jimmunol.166.11.6893","article-title":"Blockade of CD40 ligand suppresses chronic experimental myasthenia gravis by down-regulation of Th1 differentiation and up-regulation of CTLA-4","volume":"166","author":"Im","year":"2001","journal-title":"J Immunol"},{"issue":"12","key":"10.1007\/s13311-022-01181-3_bib118","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1111\/ajt.14872","article-title":"Characterization of the in vitro and in vivo properties of CFZ 533, a blocking and non-depleting anti-CD 40 monoclonal antibody","volume":"18","author":"Ristov","year":"2018","journal-title":"Am J Transplant"},{"issue":"2","key":"10.1007\/s13311-022-01181-3_bib119","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.4049\/jimmunol.169.2.1077","article-title":"Resistance to experimental autoimmune myasthenia gravis in IL-6-deficient mice is associated with reduced germinal center formation and C3 production","volume":"169","author":"Deng","year":"2002","journal-title":"J Immunol"},{"issue":"2","key":"10.1007\/s13311-022-01181-3_bib120","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jaut.2010.12.001","article-title":"Blocking of IL-6 suppresses experimental autoimmune myasthenia gravis","volume":"36","author":"Aricha","year":"2011","journal-title":"J Autoimmun"},{"issue":"9","key":"10.1007\/s13311-022-01181-3_bib121","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1073\/pnas.1017385108","article-title":"Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica","volume":"108","author":"Chihara","year":"2011","journal-title":"Proc Natl Acad Sci"},{"issue":"6","key":"10.1007\/s13311-022-01181-3_bib122","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.nmd.2017.03.007","article-title":"Beneficial effect of tocilizumab in myasthenia gravis refractory to rituximab","volume":"27","author":"Jonsson","year":"2017","journal-title":"Neuromuscul Disord"},{"issue":"2","key":"10.1007\/s13311-022-01181-3_bib123","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/00005072-198003000-00005","article-title":"Ultrastructural localization of the terminal and lytic ninth complement component (C9) at the motor end-plate in myasthenia gravis","volume":"39","author":"Sahashi","year":"1980","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1007\/s13311-022-01181-3_bib124","doi-asserted-by":"crossref","first-page":"317","DOI":"10.2147\/ITT.S261414","article-title":"Complement inhibition for the treatment of myasthenia gravis","volume":"9","author":"Mantegazza","year":"2020","journal-title":"ImmunoTargets and Therapy"},{"issue":"9","key":"10.1007\/s13311-022-01181-3_bib125","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1634\/theoncologist.2008-0086","article-title":"FDA report: eculizumab (Soliris\u00ae) for the treatment of patients with paroxysmal nocturnal hemoglobinuria","volume":"13","author":"Dmytrijuk","year":"2008","journal-title":"Oncologist"},{"issue":"23","key":"10.1007\/s13311-022-01181-3_bib126","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic\u2013uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1007\/s13311-022-01181-3_bib127","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in aquaporin-4\u2013positive neuromyelitis optica spectrum disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1007\/s13311-022-01181-3_bib128","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"The Lancet Neurology"},{"key":"10.1007\/s13311-022-01181-3_bib129","doi-asserted-by":"crossref","unstructured":"Howard Jr JF, Karam C, Yountz M, O'Brien FL, Mozaffar T, REGAIN Study Group. Long\u2010term efficacy of eculizumab in refractory generalized myasthenia gravis: responder analyses. Ann Clin Transl Neurol. 2021.","DOI":"10.1002\/acn3.51376"},{"issue":"8","key":"10.1007\/s13311-022-01181-3_bib130","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1007\/s11136-019-02148-2","article-title":"Eculizumab improves fatigue in refractory generalized myasthenia gravis","volume":"28","author":"Andersen","year":"2019","journal-title":"Qual Life Res"},{"key":"10.1007\/s13311-022-01181-3_bib131","doi-asserted-by":"crossref","unstructured":"Mantegazza R, O\u2019Brien FL, Yountz M, Howard Jr JF, REGAIN study group, Gabriel Mazia C, Wilken M, Barroso F, Saba J, Rugiero M, Bettini M. Consistent improvement with eculizumab across muscle groups in myasthenia gravis. Ann Clin Transl Neurol. 2020;7(8):1327\u201339.","DOI":"10.1002\/acn3.51121"},{"key":"10.1007\/s13311-022-01181-3_bib132","doi-asserted-by":"crossref","unstructured":"Vissing J, Jacob S, Fujita KP, O'Brien F, Howard JF, REGAIN study group. \u2018Minimal symptom expression in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab. J Neurol. 2020;267(7):1991.","DOI":"10.1007\/s00415-020-09770-y"},{"issue":"4","key":"10.1007\/s13311-022-01181-3_bib133","doi-asserted-by":"crossref","first-page":"e610","DOI":"10.1212\/WNL.0000000000011207","article-title":"Post-intervention status in patients with refractory myasthenia gravis treated with eculizumab during REGAIN and its open-label extension","volume":"96","author":"Mantegazza","year":"2021","journal-title":"Neurology"},{"issue":"1","key":"10.1007\/s13311-022-01181-3_bib134","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/mus.26447","article-title":"Long-term safety and efficacy of eculizumab in generalized myasthenia gravis","volume":"60","author":"Muppidi","year":"2019","journal-title":"Muscle Nerve"},{"issue":"5","key":"10.1007\/s13311-022-01181-3_bib135","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1001\/jamaneurol.2019.5125","article-title":"Clinical effects of the self-administered subcutaneous complement inhibitor zilucoplan in patients with moderate to severe generalized myasthenia gravis: results of a phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial","volume":"77","author":"Howard","year":"2020","journal-title":"JAMA Neurol"},{"issue":"9","key":"10.1007\/s13311-022-01181-3_bib136","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/nri2155","article-title":"FcRn: the neonatal Fc receptor comes of age","volume":"7","author":"Roopenian","year":"2007","journal-title":"Nat Rev Immunol"},{"issue":"7","key":"10.1007\/s13311-022-01181-3_bib137","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"The Lancet Neurology"},{"key":"10.1007\/s13311-022-01181-3_bib138","unstructured":"Bril V, Benatar M, Brock M, Greve B, Kiessling P, Woltering F, Van den Bergh P. Proof-of-concept and safety of the anti-FcRn antibody rozanolixizumab in patients with moderate-to-severe generalized myasthenia gravis (GMG): a phase 2a study (S43. 001)."},{"key":"10.1007\/s13311-022-01181-3_bib139","unstructured":"Momenta Pharmaceuticals Announces Positive Topline Data from Interim Analysis of Phase 2 Vivacity-MG Study of Nipocalimab (M281) in Generalized Myasthenia Gravis (gMG). https:\/\/www.momentapharma.com\/inves-tors-and-news\/press-releases\/press-releases-details\/2020\/Momenta-Pharmaceuticals-Announces-Positive-Topline-Data-from-Interim-Analysis-of-Phase-2-Vivacity-MG-Study-of-Nip-ocalimab-M281-in-Generalized-Myasthenia-Gravis-gMG\/default.Aspx 2020."}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-022-01181-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13311-022-01181-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187874792301111X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187874792301111X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-022-01181-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:58:48Z","timestamp":1761807528000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S187874792301111X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":139,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S187874792301111X"],"URL":"https:\/\/doi.org\/10.1007\/s13311-022-01181-3","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antibody Therapies in Autoimmune Neuromuscular Junction Disorders: Approach to Myasthenic Crisis and Chronic Management","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-022-01181-3","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2022 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}